Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Incyte Corp, Medical Devices Deals, 2011 to YTD 2017 11
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Incyte Corp, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 14
Partnerships 15
AstraZeneca and MedImmune Expands Agreement with Incyte 15
Bristol-Myers Squibb and Incyte Enter into Agreement 16
Incyte Enters into Research Agreement with Abramson Cancer Center 17
Incyte Enters into Distribution Agreement with GENESIS Pharma 18
Incyte Enters into Agreement with Moffitt Cancer Center 19
Incyte Enters into Agreement with AstraZeneca 20
Incyte Extends Partnership with Merck 21
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 22
Licensing Agreements 23
Incyte Enters into Licensing Agreement with MacroGenics 23
Incyte Enters into Licensing Agreement with Calithera Biosciences 24
Incyte Enters into Licensing Agreement with Merus 26
Incyte Amends Licensing Agreement with ARIAD Pharma 28
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 29
Incyte Amends Licensing Agreement with Agenus 30
Equity Offering 32
Incyte Raises USD650 Million in Public Offering of Shares 32
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 34
Agenus Raises USD35 Million in Private Placement of Common Stock 36
Debt Offering 38
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 38
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 40
Acquisition 42
Gilead Sciences May Acquire Incyte 42
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 43
Incyte Corp – Key Competitors 45
Incyte Corp – Key Employees 46
Incyte Corp – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Financial Announcements 48
Oct 31, 2017: Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs 48
May 04, 2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs 50
Feb 14, 2017: Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs 52
Nov 01, 2016: Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs 55
Aug 09, 2016: Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs 57
May 09, 2016: Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs 60
Feb 11, 2016: Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs 62
Corporate Communications 64
Oct 30, 2017: Incyte Names New Member to Its Board of Directors 64
Oct 06, 2017: Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware 65
Product News 66
11/30/2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors 66
09/27/2016: NCCN Guidelines Recommend Jakafi (ruxolitinib) for the Treatment of Myelofibrosis 67
06/23/2016: FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD) 68
04/20/2017: Incyte Presents Data on INCB050465 At at the 2017 ASCO Annual Meeting 69
04/18/2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 70
04/18/2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 71
03/07/2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 72
03/07/2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 73
01/21/2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody 74
Jan 11, 2016: Incyte Presents Significant Progress in its Development Portfolio 75
Product Approvals 77
Jul 25, 2016: Calithera Biosciences Announces FDA Acceptance of Investigational New Drug Application for CB-1158, a Novel Arginase Inhibitor Targeting an Immune Metabolic Checkpoint 77
Feb 18, 2016: Health Canada approves PrJakavi (ruxolitinib) for polycythemia vera, a chronic blood cancer 78
Clinical Trials 79
Nov 10, 2017: MacroGenics Announces Poster Presentations on MGA012 at 32nd Annual SITC Meeting 2017 79
Oct 19, 2017: Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda 80
Jun 05, 2017: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting 81
Apr 20, 2017: Incyte Presents Data on CB-1158 at the 2017 ASCO Annual Meeting 82
Mar 28, 2017: Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study 83
Dec 04, 2016: Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi (ruxolitinib) 84
Nov 11, 2016: Calithera Biosciences Announces Presentation on CB-1158 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting 85
Sep 28, 2016: Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda (Pembrolizumab) 86
Sep 15, 2016: Calithera Announces First Patient Dosed in a Phase I Study of CB-1158, the First-in-Class Inhibitor of the Immuno-Oncology Target Arginase 87
Sep 07, 2016: Calithera announces poster presentation on CB-1158 preclinical results at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 88
Jul 19, 2016: Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016 89
Jun 22, 2016: Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study 90
Jun 10, 2016: New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera 91
Jun 06, 2016: Five-year Results from Phase 3 Study of Jakafi (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis 92
May 19, 2016: Incyte Highlights Jakafi (ruxolitinib) Abstract to be Presented at the 2016 ASCO and EHA Annual Meetings 93
Apr 18, 2016: Calithera Biosciences Announces Preclinical Presentation of CB-1158 at the American Association for Cancer Research Annual Meeting 2016 95
Jan 27, 2016: Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP 96
Jan 22, 2016: Calithera Biosciences Announces Abstract Selected for Oral Presentation at the 2016 Keystone Symposia 97
Other Significant Developments 98
Feb 29, 2016: Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99
Incyte Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Incyte Corp, Deals By Therapy Area, 2011 to YTD 2017 10
Incyte Corp, Medical Devices Deals, 2011 to YTD 2017 11
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 14
AstraZeneca and MedImmune Expands Agreement with Incyte 15
Bristol-Myers Squibb and Incyte Enter into Agreement 16
Incyte Enters into Research Agreement with Abramson Cancer Center 17
Incyte Enters into Distribution Agreement with GENESIS Pharma 18
Incyte Enters into Agreement with Moffitt Cancer Center 19
Incyte Enters into Agreement with AstraZeneca 20
Incyte Extends Partnership with Merck 21
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 22
Incyte Enters into Licensing Agreement with MacroGenics 23
Incyte Enters into Licensing Agreement with Calithera Biosciences 24
Incyte Enters into Licensing Agreement with Merus 26
Incyte Amends Licensing Agreement with ARIAD Pharma 28
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 29
Incyte Amends Licensing Agreement with Agenus 30
Incyte Raises USD650 Million in Public Offering of Shares 32
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 34
Agenus Raises USD35 Million in Private Placement of Common Stock 36
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 38
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 40
Gilead Sciences May Acquire Incyte 42
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 43
Incyte Corp, Key Competitors 45
Incyte Corp, Key Employees 46
Incyte Corp, Subsidiaries 47
